beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis - PubMed (original) (raw)
beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis
T Miyata et al. J Clin Invest. 1993 Sep.
Abstract
beta 2-Microglobulin (beta 2M) is a major constituent of amyloid fibrils in hemodialysis-associated amyloidosis, a complication of long-term hemodialysis patients. Amyloid fibril proteins were isolated from connective tissues forming carpal tunnels in hemodialysis patients with carpal tunnel syndrome. Two-dimensional polyacrylamide gel electrophoresis and Western blotting demonstrated that most of the beta 2M forming amyloid fibrils exhibited a more acidic pI value than normal beta 2M. This acidic beta 2M was also found in a small fraction of beta 2M in sera and urine from these patients, whereas heterogeneity was not observed in healthy individuals. We purified acidic and normal beta 2M from the urine of long-term hemodialysis patients and compared their physicochemical and immunochemical properties. Acidic beta 2M, but not normal beta 2M, was brown in color and fluoresced, both of which are characteristics of advanced glycation end products (AGEs) of the Maillard reaction. Immunochemical studies showed that acidic beta 2M reacted with anti-AGE antibody and also with an antibody against an Amadori product, an early product of the Maillard reaction, but normal beta 2M did not react with either antibody. Incubating normal beta 2M with glucose in vitro resulted in a shift to a more acidic pI, generation of fluorescence, and immunoreactivity to the anti-AGE antibody. The beta 2M forming amyloid fibrils also reacted with anti-AGE antibody. These data provided evidence that AGE-modified beta 2M is a dominant constituent of the amyloid deposits in hemodialysis-associated amyloidosis.
Similar articles
- Beta 2-microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis.
Iida Y, Miyata T, Inagi R, Sugiyama S, Maeda K. Iida Y, et al. Biochem Biophys Res Commun. 1994 Jun 30;201(3):1235-41. doi: 10.1006/bbrc.1994.1837. Biochem Biophys Res Commun. 1994. PMID: 8024566 - Ultrastructural localization of advanced glycation end products and beta2-microglobulin in dialysis amyloidosis.
Brancaccio D, Gallieni M, Niwa T, Braidotti P, Coggi G. Brancaccio D, et al. J Nephrol. 2000 Mar-Apr;13(2):129-36. J Nephrol. 2000. PMID: 10858976 - Haemodialysis-associated beta 2M amyloidosis: current controversies.
Stein G, Sperschneider H, Fünfstück R, Ritz E. Stein G, et al. Nephrol Dial Transplant. 1994;9 Suppl 3:48-50. Nephrol Dial Transplant. 1994. PMID: 8072726 Review.
Cited by
- Beta-2 Microglobulin Amyloidosis: Past, Present, and Future.
Portales-Castillo I, Yee J, Tanaka H, Fenves AZ. Portales-Castillo I, et al. Kidney360. 2020 Oct 21;1(12):1447-1455. doi: 10.34067/KID.0004922020. eCollection 2020 Dec 31. Kidney360. 2020. PMID: 35372889 Free PMC article. Review. - Understanding the Role of Protein Glycation in the Amyloid Aggregation Process.
Sirangelo I, Iannuzzi C. Sirangelo I, et al. Int J Mol Sci. 2021 Jun 21;22(12):6609. doi: 10.3390/ijms22126609. Int J Mol Sci. 2021. PMID: 34205510 Free PMC article. Review. - Optical Method and Biochemical Source for the Assessment of the Middle-Molecule Uremic Toxin β2-Microglobulin in Spent Dialysate.
Paats J, Adoberg A, Arund J, Fridolin I, Lauri K, Leis L, Luman M, Tanner R. Paats J, et al. Toxins (Basel). 2021 Mar 31;13(4):255. doi: 10.3390/toxins13040255. Toxins (Basel). 2021. PMID: 33807387 Free PMC article. - Multiple Forms of Multifunctional Proteins in Health and Disease.
Espinosa-Cantú A, Cruz-Bonilla E, Noda-Garcia L, DeLuna A. Espinosa-Cantú A, et al. Front Cell Dev Biol. 2020 Jun 10;8:451. doi: 10.3389/fcell.2020.00451. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32587857 Free PMC article. Review. - Nω -(Carboxymethyl)arginine Is One of the Dominant Advanced Glycation End Products in Glycated Collagens and Mouse Tissues.
Kinoshita S, Mera K, Ichikawa H, Shimasaki S, Nagai M, Taga Y, Iijima K, Hattori S, Fujiwara Y, Shirakawa JI, Nagai R. Kinoshita S, et al. Oxid Med Cell Longev. 2019 Sep 10;2019:9073451. doi: 10.1155/2019/9073451. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 31583049 Free PMC article.
References
- N Engl J Med. 1988 May 19;318(20):1315-21 - PubMed
- J Clin Pathol. 1988 Feb;41(2):158-62 - PubMed
- Clin Nephrol. 1988 Sep;30(3):158-63 - PubMed
- Prog Clin Biol Res. 1989;304:1-22 - PubMed
- Kidney Int. 1989 Oct;36(4):675-81 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous